BUZZ-Trevi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> slips on $100 mln stock sale plans** Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise
** New Haven, Connecticut-based firm commences $100 mln stock offering
** Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners
** Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026
** With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data
** TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.